Mirum Pharmaceuticals, Inc. MIRM Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product sales, net by Product | ||||||
| Bile Acid Medicines | $169.02M+24.8% | $161.31M+31.0% | $154.1M+33.0% | $144.5M+54.2% | $135.4M+114% | |
| Livmarli | $400.59M+64.4% | $360.01M+68.8% | $317.71M+66.6% | $284.6M+67.1% | $243.67M+56.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mirum Pharmaceuticals, Inc. break its business down?
- Mirum Pharmaceuticals, Inc. (MIRM) reports product sales, net by product across 2 parts — Bile Acid Medicines and Livmarli. Each is extracted from the segment footnotes and tracked over time.
- Where does Mirum Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mirum Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
